Last updated: August 10, 2026
Memantine hydrochloride and donepezil hydrochloride extended-release is marketed in the United States as Namzaric, an oral combination capsule for moderate-to-severe Alzheimer’s disease in patients stabilized on memantine and donepezil. The product combines extended-release memantine hydrochloride with immediate-release donepezil hydrochloride in a multiparticulate dosage form. Its principal commercial opportunities are generic substitution, alternative sprinkle formats, manufacturing-cost reduction, and differentiated combination products that preserve pharmacokinetic performance while improving administration for patients with dysphagia.
What is the FDA status of memantine and donepezil hydrochlorides extended-release?
Namzaric is approved under FDA NDA 206439. The product is available in four fixed-dose combinations:
| Memantine hydrochloride extended-release |
Donepezil hydrochloride immediate-release |
| 7 mg |
10 mg |
| 14 mg |
10 mg |
| 21 mg |
10 mg |
| 28 mg |
10 mg |
The approved dosage is once daily in the evening. Namzaric is intended for patients taking memantine hydrochloride extended-release and donepezil hydrochloride at the corresponding doses. The capsule may be swallowed whole or opened and sprinkled on applesauce without chewing, according to the prescribing information.[1]
The product is a combination of two established active pharmaceutical ingredients:
- Memantine hydrochloride is an N-methyl-D-aspartate receptor antagonist.
- Donepezil hydrochloride is an acetylcholinesterase inhibitor.
- Memantine is delivered in an extended-release format.
- Donepezil is delivered in an immediate-release format.
The regulatory design is therefore more complex than a conventional fixed-dose tablet. A successful generic must reproduce the pharmacokinetic behavior of both active ingredients and maintain the approved administration options.
What excipients are used in Namzaric capsules?
Namzaric uses a multiparticulate formulation in which the active ingredients are incorporated into separate or functionally distinct bead populations. The formulation includes excipients for pellet formation, drug layering, controlled release, capsule filling, and immediate-release delivery.
Public labeling identifies excipient classes and capsule components, while the precise quantitative composition and manufacturing process are generally controlled by the application holder. The relevant excipient functions include:
| Excipient function |
Strategic purpose |
| Sugar or inert core material |
Provides a spherical substrate for drug layering |
| Binder |
Promotes adhesion of active ingredient to the pellet core |
| Polymer coating |
Controls memantine release over the dosing interval |
| Pore former or permeability modifier |
Adjusts water ingress and drug diffusion |
| Plasticizer |
Improves coating-film flexibility and reduces cracking |
| Anti-tacking agent |
Prevents pellet agglomeration during coating |
| Capsule shell |
Enables multiparticulate oral delivery and sprinkle administration |
| Colorants and opacifiers |
Supports product identification and light protection |
The most important formulation distinction is the release-control system for memantine. Donepezil must release promptly, while memantine must produce an extended exposure profile comparable to the reference product. A generic manufacturer can use different excipients from the reference product if the formulation satisfies FDA requirements for pharmaceutical equivalence, bioequivalence, stability, safety, and labeling.
How does the multiparticulate excipient strategy work?
Multiparticulate delivery separates release control from the capsule shell. The capsule is primarily a container. Drug release is governed by the composition, thickness, porosity, and mechanical integrity of the coated pellets.
A practical reference-product design is likely to include:
- Immediate-release donepezil particles or pellets.
- Memantine pellets coated with a water-insoluble or water-permeable polymer system.
- A blend of pellet populations filled into a hard gelatin capsule.
- A sprinkle-compatible particle size distribution that limits segregation and supports uniform dosing.
This structure provides several development advantages:
- It reduces the risk that a single matrix tablet will release both drugs incorrectly.
- It supports capsule opening and sprinkling on soft food.
- It allows separate optimization of donepezil and memantine release.
- It can improve dose uniformity across the four strengths.
- It permits scale-up through fluid-bed coating and multiparticulate blending.
The principal technical risk is pellet-to-pellet variability. Small changes in coating weight gain, polymer dispersion, drying temperature, spray rate, or pellet size can materially alter memantine release. Manufacturing controls must therefore focus on coating uniformity, residual moisture, pellet friability, blend segregation, and dissolution across the full shelf life.
What excipient attributes are critical for generic development?
Release-control polymers
The memantine component requires a reproducible extended-release coating. Candidate systems may include ethylcellulose, methacrylate copolymers, hypromellose-based barriers, or combinations of water-soluble and water-insoluble polymers.
The best commercial system will balance:
- Release similarity to the reference product.
- Low coating weight.
- Resistance to mechanical damage.
- Compatibility with aqueous processing.
- Stable dissolution after storage.
- Low sensitivity to food and gastrointestinal conditions.
A coating that depends heavily on a narrow process window increases manufacturing cost and batch-failure risk.
Binders and drug-layering excipients
Polyvinylpyrrolidone, hydroxypropyl cellulose, hypromellose, and related binders can support drug layering. The binder must provide adhesion without creating dense films that slow drug release unpredictably.
For a high-dose memantine strength, drug loading and pellet size become important. Excessively high drug loading can produce fragile pellets or nonuniform coating surfaces. Low drug loading increases the number of processing steps and the volume of capsule fill.
Plasticizers and anti-tacking agents
Plasticizers improve coating flexibility but can migrate, volatilize, or affect long-term dissolution. Anti-tacking agents such as talc or colloidal silicon dioxide can reduce agglomeration during fluid-bed coating. Their concentration must be controlled because excess anti-tacking material can reduce coating adhesion or alter permeability.
Capsule shell materials
Hard gelatin capsules are compatible with sprinkle administration but are sensitive to moisture. Hypromellose capsules can offer a lower-moisture alternative, although the change may require comparative stability, dissolution, and bioequivalence evaluation.
Capsule selection affects:
- Moisture transmission.
- Shell brittleness.
- Fill weight.
- Printing performance.
- Compatibility with packaging.
- Patient handling after opening.
A generic manufacturer should avoid assuming that a capsule shell change is commercially neutral. It can affect both stability and the mechanical integrity of coated pellets during encapsulation.
What formulation patents protect the product?
The principal intellectual-property risk is likely to center on the combination and release architecture rather than on basic use of memantine or donepezil. Relevant claim categories include:
- Fixed-dose combinations of memantine and donepezil.
- Once-daily administration.
- Extended-release memantine combined with immediate-release donepezil.
- Multiparticulate or pellet dosage forms.
- Sprinkle administration.
- Specific dissolution profiles.
- Treatment of moderate-to-severe Alzheimer’s disease.
- Manufacturing methods for coated particles and capsule filling.
The current FDA Orange Book should be used to identify active listed patents, pediatric exclusivity, patent-use codes, and expiration information for NDA 206439.[2] Patent expiration dates can differ from nominal twenty-year terms because of terminal disclaimers, patent-term adjustment, patent-term extension, and regulatory exclusivity.
The practical freedom-to-operate question is whether a proposed ANDA formulation infringes an unexpired claim covering the combination, release profile, dosage form, or manufacturing process. Using a different polymer system does not eliminate risk if a patent claim is drafted broadly around the combination or pharmacokinetic profile.
When does Namzaric lose exclusivity?
Namzaric’s regulatory exclusivity and patent protection are separate issues.
The product contains previously approved active ingredients, so it does not receive the standard five-year new chemical entity exclusivity associated with an entirely new active ingredient. Combination-product exclusivity may arise from qualifying clinical investigations, but that period is distinct from patent protection and does not necessarily prevent all later filings once it expires.
Generic entry depends on:
- Expiration or successful challenge of listed patents.
- The ANDA applicant’s Paragraph IV position.
- FDA acceptance of bioequivalence data.
- Any 30-month stay arising from timely patent litigation.
- Settlement terms between the brand and generic applicants.
- Commercial decisions by the applicant after approval.
A current Orange Book review is necessary for definitive listed-patent expiration dates and active patent-use codes. The relevant product identifier is NDA 206439, under the Namzaric trade name.[2]
What Paragraph IV challenges and litigation affect generic entry?
A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic. For Namzaric, the most likely challenge targets are combination, extended-release, and dosage-form patents.
The commercial sequence is:
- An ANDA applicant submits a Paragraph IV certification.
- The patent holder receives notice.
- The patent holder may file infringement litigation within 45 days.
- A timely lawsuit can trigger a statutory 30-month stay of FDA approval, subject to court action.
- The first substantially complete Paragraph IV applicant may qualify for 180-day generic exclusivity if statutory conditions are satisfied.
The most important diligence documents are FDA’s Orange Book, FDA Paragraph IV litigation information, PACER litigation records, and any publicly filed settlement agreements.[2-4]
There is no biosimilar pathway for Namzaric. Both active ingredients are small molecules. Competition proceeds through the ANDA pathway, not the 351(k) biosimilar pathway.
What generic launch risks exist?
The primary launch risks are formulation and litigation risks rather than active-ingredient availability.
| Risk |
Commercial impact |
| Failure to match memantine release |
Bioequivalence failure or additional studies |
| Food-effect divergence |
Labeling restrictions or delayed approval |
| Dose dumping under alcohol conditions |
Regulatory deficiency and safety concern |
| Pellet segregation |
Content-uniformity failures |
| Sprinkle performance failure |
Inability to match the reference label |
| Patent litigation |
Approval delay and legal expense |
| Limited physician substitution |
Slower market conversion |
| Low capsule-fill efficiency |
Margin erosion |
| Inadequate stability |
Short shelf life or packaging cost |
Extended-release products require dissolution testing across multiple media and time points. A generic may pass conventional comparative dissolution but fail in clinically relevant conditions if the release mechanism is too sensitive to pH, agitation, alcohol, or food.
The sprinkle claim is commercially important. Many Alzheimer’s patients have dysphagia, and caregivers may administer medication with soft food. A product that cannot demonstrate equivalent sprinkle performance may be technically approvable with different labeling but commercially disadvantaged.
What are the strongest excipient-led commercial opportunities?
Lower-cost coated multiparticulates
The clearest opportunity is a process-efficient pellet platform using aqueous coating, high drug loading, and a common intermediate across all four strengths. A shared memantine pellet platform can reduce development and manufacturing complexity if capsule fill weights are adjusted without creating segregation or dose-uniformity problems.
Hypromellose capsule alternatives
A lower-moisture capsule shell may improve stability and simplify packaging. The commercial benefit depends on whether the shell reduces blister or bottle requirements and maintains equivalent dissolution and sprinkle behavior.
Sprinkle-focused presentations
A generic or follow-on product can compete through caregiver usability. Potential designs include:
- Capsules with improved opening and pouring characteristics.
- Pellets optimized for soft-food administration.
- Unit-dose sachets containing multiparticulates.
- Ready-to-administer sprinkle granules.
- Alternative capsule sizes that reduce swallowing difficulty.
A sachet or granule product may require a different regulatory strategy from a conventional ANDA, particularly if the dosage form, administration method, or release system differs materially from the reference product.
Alternative fixed-dose strengths
The approved Namzaric strengths contain 10 mg donepezil with four memantine doses. A 505(b)(2) product could explore additional dose ratios or titration strengths, but such changes may require clinical justification and would face a higher regulatory burden than an ANDA.
Manufacturing and licensing opportunities
Excipient suppliers with expertise in functional coatings, pelletization, capsule materials, and multiparticulate process analytics can pursue:
- Contract development of memantine extended-release pellets.
- Licensing of coating compositions.
- Contract manufacturing of drug-layered beads.
- Technology transfer for fluid-bed coating.
- Analytical packages supporting dissolution similarity.
- Packaging systems that control moisture and preserve pellet integrity.
The most defensible supplier position is a validated platform with demonstrated performance across multiple dose strengths, rather than a commodity excipient sold without process know-how.
How does Namzaric compare with separate memantine and donepezil products?
| Attribute |
Namzaric |
Separate products |
| Dosing |
Once-daily fixed combination |
Separate prescriptions and administration |
| Memantine |
Extended release |
Extended-release or immediate-release options |
| Donepezil |
Immediate release within capsule |
Usually tablet, orally disintegrating tablet, or other approved form |
| Adherence |
Fewer administration events |
Greater regimen complexity |
| Dose flexibility |
Limited to marketed ratios |
Individual dose adjustment |
| Generic competition |
Combination ANDA |
Separate generic markets |
| Caregiver administration |
Capsule can be sprinkled |
Depends on individual product |
| Formulation complexity |
High |
Lower for conventional products |
The combination product has a convenience advantage but less dose flexibility. Physicians may retain separate products when titrating one component independently, while fixed-dose therapy is attractive after stabilization.
How strong is the patent estate and what is the commercial outlook?
The patent estate should be assessed claim by claim across four categories: combination therapy, extended-release memantine, multiparticulate dosage forms, and administration methods. Broad combination claims can create material entry risk even when a generic uses different excipients. Narrow coating or dissolution claims are more susceptible to design-around strategies.
Commercial opportunity is strongest where a developer can combine:
- A legally differentiated formulation.
- Robust extended-release dissolution.
- Reliable sprinkle performance.
- Low-cost pellet manufacturing.
- Adequate supply of specialty coating excipients.
- A credible Paragraph IV or noninfringement position.
The product’s market is limited to Alzheimer’s disease, but the caregiver-administered nature of treatment increases the value of ease of use. A low-cost generic capsule is the most direct opportunity. A differentiated sprinkle or granule product can command greater value if it improves administration without creating a substantial regulatory burden.
Key Takeaways
- Namzaric combines extended-release memantine hydrochloride with immediate-release donepezil hydrochloride in a once-daily multiparticulate capsule.
- The key excipient challenge is controlling memantine release while preserving immediate donepezil release and sprinkle performance.
- Coating polymers, binders, plasticizers, anti-tacking agents, capsule shells, and moisture-control packaging drive product performance.
- The main generic pathway is an ANDA supported by comparative pharmacokinetic and dissolution data.
- There is no biosimilar pathway because both active ingredients are small molecules.
- Patent risks are concentrated in combination, release profile, multiparticulate, method-of-use, and administration claims.
- Commercial opportunities include lower-cost pellet manufacture, alternative capsule shells, caregiver-friendly sprinkle products, and contract coating or formulation platforms.
- Current Orange Book and FDA litigation records control the definitive assessment of active patents, Paragraph IV filings, and entry timing.
FAQs
Can memantine and donepezil extended-release be formulated as a single tablet?
Yes, but a single matrix tablet would require separate control of immediate donepezil release and extended memantine release. A multiparticulate capsule is technically more flexible and more compatible with sprinkle administration.
Which excipient is most important for memantine extended release?
The release-control polymer system is the most important excipient group. Polymer permeability, coating thickness, plasticizer level, and pore structure determine the memantine dissolution profile.
Can a generic use different excipients from Namzaric?
Yes. FDA generally does not require identical inactive ingredients for an ANDA, subject to safety, pharmaceutical equivalence, bioequivalence, inactive-ingredient limits, and product-specific requirements.[5]
Is a sprinkle formulation commercially valuable for Alzheimer’s drugs?
Yes. Sprinkle administration can reduce swallowing barriers for patients with dysphagia and simplify caregiver dosing. The product must preserve dose uniformity, stability, and release performance after administration on soft food.
Could a new memantine-donepezil granule product qualify under the 505(b)(2) pathway?
Potentially. A materially different dosage form, strength, release system, or administration method may require a 505(b)(2) application rather than an ANDA. The pathway depends on the extent of reliance on the reference product and the additional clinical or pharmaceutical data required.
References
-
U.S. Food and Drug Administration. (2023). Namzaric (memantine hydrochloride and donepezil hydrochloride) extended-release capsules: Prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2024). Paragraph IV drug product and patent information. FDA.
-
U.S. Courts. (2024). PACER case locator and federal patent litigation records. Administrative Office of the U.S. Courts.
-
U.S. Food and Drug Administration. (2022). Inactive ingredient database. FDA.
